Utilizing Autologous Multipotent Mesenchymal Stromal Cells and β-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

• Published in: BioMed research international Vol. 2016; no. 2016; pp. 1 - 12
• Main Authors: Syková, Eva, Bezrouk, Aleš, Kočí, Zuzana, Palicka, Vladimir, Urban, Karel, Brtková, Jindra, Kučera, Tomáš, Filip, S., Šponer, Pavel, Syka, Michael
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01-01-2016
• Subjects: Aged; Arthroplasty, Replacement, Hip; Bone Regeneration - physiology; Bone Remodeling - drug effects; Bone Remodeling - physiology; Calcium Phosphates - therapeutic use; Cancellous Bone - drug effects; Cancellous Bone - physiopathology; Cancellous Bone - surgery; Clinical Study; Female; Femur - physiopathology; Femur - surgery; Humans; Male; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal Stromal Cells; Middle Aged; Tissue Scaffolds - chemistry; Transplantation, Autologous; Treatment Outcome
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2016/2076061

The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous β-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or β-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P<0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of β-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P<0.05). Using autologous mesenchymal stromal cells combined with a β-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).